Swimming with sharks: Tekmira CEO comments on Ebola R&D challenge; Cytori raising $13.5M;

@FierceBiotech: New special report: Top 7 life sciences public investors. Feature | Follow @FierceBiotech

@JohnCFierce: BIA did a report on bio-fundraising in the U.K. Hard to see where the promo ends and the analysis begins. Very Yank. More | Follow @JohnCFierce

@DamianFierce:  | Follow @DamianFierce

@EmilyMFierce: Hmmm... Cancer tumours destroyed by berry found in Queensland rainforest. More from The Guardian | Follow @EmilyMFierce

> In an interview, Tekmira ($TKMR) CEO Mark Murray said that developing a therapy for Ebola is like swimming in "shark-infested water." Story

> San Diego-based Cytori Therapeutics is raising $13.5 million through a direct offering. Release

> Israel's BrainStorm Therapeutics says it gained fast-track status at the FDA for its adult stem cell therapy for ALS. Story

Medical Device News

@FierceMedDev: This week's issue of FierceDiagnostics is out! Sign up for free here. | Follow @FierceMedDev

@VarunSaxena2: Flowonix submits MRI-compatible implantable infusion pump for FDA approval. FierceDrugDelivery story | Follow @VarunSaxena2

@EmilyWFierce: Robot-assisted surgery often comes with more complications and higher costs, according to new study. More from the WSJ | Follow @EmilyWFierce

@MichaelGFierce: From our Women in Biotech Feature: Adelene Perkins of $INFI says, "Our endeavor is by definition a team sport." More | Follow @MichaelGFierce

> At least $200M paid to docs by medical device industry. Item

> Becton plans on $9.1B bridge loan to finance deal with CareFusion. Story

> EU halts distribution of GI Dynamics obesity device. News

> Preview: Boston Scientific's Watchman goes before third FDA panel. More

Pharma News

@FiercePharma: Top-read special report in FP Tues: Top 10 pharma companies by employees - 2014. Feature | Follow @FiercePharma

@CarlyHFierce: ICYMI yesterday: Bayer insists its probiotic marketing claims aren't full of hot air. Article | Follow @CarlyHFierce

> Novartis, GSK shake up executive ranks as overhaul continues. Article

> With Actavis poised to swoop in, Valeant eyes $4.5B hike in bid for Allergan. Report

Drug Delivery News

> Flat nanosheets roll drugs up and release them on command. Item

> With Roche's Herceptin, green tea component doubles drug accumulation in cancer cells. More

> Flowonix submits MRI-compatible implantable infusion pump for FDA approval. Story

> USPTO to review delivery patent in spat between Suboxone and BDSI's Bunavail. Report

> Alnylam says it wants to enter larger disease areas using partnership-driven approach. More

Diagnostics News

> MD Anderson pursues two projects targeting personalized prostate cancer testing. News

> Health Diagnostic Laboratory helps find promising predictive diabetes biomarkers. More

> Swedes, Harvard and more find success with DNA test for Afib risks. Report

> NanoString and a Harvard-affiliated hospital hope to quicken creation of new cancer tests. Story

> Quest, in transition, recruits Mayo Clinic exec to run major division. Article

Pharma Marketing News

> Analysts: Actavis-Allergan deal could create a marketing superpower. Item

> Pfizer's new #viagracommercial lights up Twitter during MLB playoffs--and not in a good way. More

> Merck hops onto HBCU network to step up its brand in the African-American community. Report

> Hand out prizes for adherence? West and HealthPrize team up to test the idea. Story

> Balking at marketing slapdown, Galderma declares itself pharma non grata. Article

Suggested Articles

All 12 members of an FDA advisory committee voted to recommend the approval of teprotumumab for a rare, autoimmune eye disease.

Early data out of former Fierce 15 winner Gritstone Oncology have been heralded as a big win for the early-stage biotech by analysts.

Biogen will drop work on gosuranemab in progressive supranuclear palsy but continue on in Alzheimer's.